Compare Novavax Inc (NVAX) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Synopsys, Inc. — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Synopsys, Inc. trades at $390 (market cap $72.47B). The key difference: Synopsys, Inc. is far larger — about 55.7× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| NVAX | SNPS | |
|---|---|---|
Market Cap | $1.30B | $72.47B |
Sector | Health | Technology |
52-Week High | $11.19 | $645.59 |
52-Week Low | $6.22 | $378.46 |
Enterprise Value | $800.50M | $80.82B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
